Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
RVTY 
Revvity Inc. (RVTY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/20/2026: RVTY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $119.56
1 Year Target Price $119.56
| 10 | Strong Buy |
| 2 | Buy |
| 7 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 11.65B USD | Price to earnings Ratio 48.7 | 1Y Target Price 119.56 |
Price to earnings Ratio 48.7 | 1Y Target Price 119.56 | ||
Volume (30-day avg) 19 | Beta 1.09 | 52 Weeks Range 81.25 - 120.05 | Updated Date 02/22/2026 |
52 Weeks Range 81.25 - 120.05 | Updated Date 02/22/2026 | ||
Dividends yield (FY) 0.28% | Basic EPS (TTM) 2.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date 2026-02-02 | When Before Market | Estimate 1.58 | Actual 1.7 |
Profitability
Profit Margin 8.45% | Operating Margin (TTM) 19.03% |
Management Effectiveness
Return on Assets (TTM) 2.23% | Return on Equity (TTM) 3.22% |
Valuation
Trailing PE 48.7 | Forward PE 16.72 | Enterprise Value 12999008166 | Price to Sales(TTM) 4.08 |
Enterprise Value 12999008166 | Price to Sales(TTM) 4.08 | ||
Enterprise Value to Revenue 4.64 | Enterprise Value to EBITDA 15.82 | Shares Outstanding 113375621 | Shares Floating 104073102 |
Shares Outstanding 113375621 | Shares Floating 104073102 | ||
Percent Insiders 0.36 | Percent Institutions 101.73 |
Upturn AI SWOT
Revvity Inc.
Company Overview
History and Background
Revvity Inc. was established in 2023 as a spin-off from PerkinElmer, a global leader in life science and diagnostics. The company inherited PerkinElmer's Health Sciences and Discovery & Analytical Solutions businesses. This strategic separation aimed to create two distinct, focused entities, with Revvity concentrating on a portfolio of differentiated instruments, reagents, consumables, and software for the diagnostics and life sciences sectors. Its evolution is marked by this significant corporate restructuring to better serve its specific markets.
Core Business Areas
- Life Sciences: Revvity provides a range of products and services for drug discovery, development, and manufacturing, including instruments, reagents, and software solutions that support research and biopharmaceutical production.
- Diagnostics: The company offers diagnostic instruments, reagents, and integrated solutions for clinical laboratories, supporting a wide array of tests including immunoassay, newborn screening, and genetic testing.
- Applied Genomics: Revvity serves the applied genomics market with solutions for areas like infectious disease testing, food safety, and environmental monitoring.
Leadership and Structure
Revvity Inc. is led by a management team with deep experience in the life sciences and diagnostics industries. The organizational structure is designed to align with its core business segments, promoting specialized focus and operational efficiency across its global operations.
Top Products and Market Share
Key Offerings
- EnSpire Multimode Plate Readers: High-performance microplate readers used in drug discovery and life science research for a variety of assays including fluorescence, luminescence, and absorbance. Competitors include BioTek Instruments (part of Agilent), Tecan, and Berthold Technologies. Market share data for specific product lines is not publicly disclosed by Revvity.
- NeoPlexu2122 Molecular Diagnostic Solutions: Automated platforms and reagents for molecular diagnostics, including infectious disease testing and genetic analysis. Key competitors include Qiagen, Thermo Fisher Scientific, and Roche Diagnostics. Specific market share for this product suite is not readily available.
- Janus Automated Workstations: Liquid handling and automation systems used in research laboratories for sample preparation, screening, and high-throughput applications. Competitors include Tecan, Hamilton Company, and Eppendorf. Market share figures are proprietary.
Market Dynamics
Industry Overview
Revvity operates within the highly dynamic and competitive life sciences and diagnostics industries. These sectors are characterized by continuous innovation, increasing demand for advanced analytical tools, the rise of personalized medicine, and a growing focus on efficiency and automation in laboratories. The diagnostics market is driven by an aging global population, increasing prevalence of chronic diseases, and advancements in molecular diagnostics. The life sciences market is fueled by robust R&D spending in pharmaceuticals and biotechnology.
Positioning
Revvity is positioned as a provider of essential tools and solutions that enable scientific discovery and improve human health. Its competitive advantages stem from its diversified portfolio inherited from PerkinElmer, its established customer base, and its focus on innovation in high-growth areas of life sciences and diagnostics. The company aims to leverage its expertise in instrument development, assay design, and data analysis to address complex scientific challenges.
Total Addressable Market (TAM)
The TAM for the life sciences tools and diagnostics markets is substantial and growing, estimated to be in the hundreds of billions of dollars globally. Revvity is positioned to capture a significant portion of this TAM through its comprehensive offerings in research, drug discovery, and clinical diagnostics. Its market position is strengthened by its ability to provide integrated solutions across multiple workflow stages.
Upturn SWOT Analysis
Strengths
- Strong legacy and established reputation from PerkinElmer's businesses.
- Diversified product portfolio across life sciences and diagnostics.
- Global sales and service infrastructure.
- Focus on innovation and R&D.
- Strategic positioning in growing market segments.
Weaknesses
- Potential integration challenges post-spin-off.
- Reliance on a few key product categories.
- Intense competition within its operational segments.
- Need to continuously invest in R&D to stay competitive.
Opportunities
- Expansion into emerging markets.
- Growth in the personalized medicine and genomics sectors.
- Strategic acquisitions to broaden portfolio or market reach.
- Leveraging digital solutions and data analytics.
- Increased demand for diagnostic testing due to global health concerns.
Threats
- Economic downturns impacting R&D spending.
- Intensifying competition from established and new players.
- Regulatory changes and compliance burdens.
- Rapid technological advancements by competitors.
- Supply chain disruptions.
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Agilent Technologies (A)
- Danaher Corporation (DHR)
- Roche Holding AG (RHHBY)
Competitive Landscape
Revvity operates in a highly competitive landscape against larger, more diversified players. Its advantages lie in its focused approach to specific niches within life sciences and diagnostics, and its ability to offer specialized solutions. However, it faces challenges from competitors with broader product portfolios, extensive global reach, and significant R&D budgets. Revvity must differentiate itself through innovation, customer service, and strategic partnerships to maintain and grow its market share.
Major Acquisitions
PerkinElmer's Health Sciences and Discovery & Analytical Solutions Businesses
- Year: 2023
- Acquisition Price (USD millions):
- Strategic Rationale: This was not an acquisition but a spin-off to create a new, independent entity focused on its core strengths in life sciences and diagnostics.
Growth Trajectory and Initiatives
Historical Growth: The historical growth trajectory of Revvity is intrinsically linked to the performance of PerkinElmer's relevant business segments prior to the spin-off. Analyzing revenue and profit trends from these segments would indicate past growth patterns.
Future Projections: Future growth projections for Revvity are typically based on analyst estimates, which consider market trends, new product pipelines, potential acquisitions, and the company's strategic initiatives. Analysts often provide revenue growth and EPS forecasts.
Recent Initiatives: Recent initiatives likely focus on solidifying its standalone identity, optimizing operations post-spin-off, and investing in key growth areas such as advanced diagnostics and innovative life science solutions. This could include strategic partnerships or R&D investments.
Summary
Revvity Inc. is a newly independent entity with a strong foundation inherited from PerkinElmer's life sciences and diagnostics segments. Its core strengths lie in its diverse product portfolio and established market presence. However, it faces significant competition and the need for continuous innovation. Key opportunities include growth in personalized medicine and emerging markets, while threats include economic headwinds and rapid technological advancements by competitors. The company's future success hinges on its ability to execute its standalone strategy effectively and capitalize on market trends.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Revvity Inc. Investor Relations
- Financial news outlets (e.g., Bloomberg, Reuters)
- Industry analyst reports
- Company filings (e.g., SEC filings)
Disclaimers:
This information is provided for informational purposes only and does not constitute financial advice. Market share data and TAM figures are estimates and may vary. Future projections are subject to change and inherent uncertainties. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Revvity Inc.
Exchange NYSE | Headquaters Waltham, MA, United States | ||
IPO Launch date 1983-04-06 | CEO, President & Director Dr. Prahlad R. Singh Ph.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 11000 | Website https://www.revvity.com |
Full time employees 11000 | Website https://www.revvity.com | ||
Revvity, Inc. provides health sciences solutions, technologies, and services. The company provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services; and instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, screening newborns for rare genetic conditions, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BioQule, BoBs, chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPatternTM, Evolution Evoya, explorer, Fontus, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Omni Bead Ruptor, Omni Bead Ruptor Elite, Omni Tip, Pannoramic, Panthera Puncher, PG-Seq, PG-Find, PreNAT II, Prime, Protein Clear, ProteinEXact, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord, VICTOR2D, and Zephyr names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.